In last trading session, Iovance Biotherapeutics Inc (NASDAQ:IOVA) saw 7.44 million shares changing hands with its beta currently measuring 1.08. Company’s recent per share price level of $3.54 trading at $0.29 or 8.92% at ring of the bell on the day assigns it a market valuation of $1.16B. That closing price of IOVA’s stock is at a discount of -301.98% from its 52-week high price of $14.23 and is indicating a premium of 10.17% from its 52-week low price of $3.18. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 8.01 million shares which gives us an average trading volume of 9.62 million if we extend that period to 3-months.
For Iovance Biotherapeutics Inc (IOVA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.31. Splitting up the data highlights that, out of 8 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 6 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Iovance Biotherapeutics Inc (NASDAQ:IOVA) trade information
Upright in the green during last session for gaining 8.92%, in the last five days IOVA remained trading in the green while hitting it’s week-highest on Thursday, 03/27/25 when the stock touched $3.54 price level, adding 3.28% to its value on the day. Iovance Biotherapeutics Inc’s shares saw a change of -52.16% in year-to-date performance and have moved 2.91% in past 5-day. Iovance Biotherapeutics Inc (NASDAQ:IOVA) showed a performance of -9.69% in past 30-days. Number of shares sold short was 67.3 million shares which calculate 5.69 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 11.5 to the stock, which implies a rise of 69.22% to its current value. Analysts have been projecting 6 as a low price target for the stock while placing it at a high target of 17. It follows that stock’s current price would drop -69.49% in reaching the projected high whereas dropping to the targeted low would mean a loss of -69.49% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 4.17% during past 5 years.
Iovance Biotherapeutics Inc (NASDAQ:IOVA)’s Major holders
Insiders are in possession of 0.63% of company’s total shares while institution are holding 84.05 percent of that, with stock having share float percentage of 84.58%. Investors also watch the number of corporate investors in a company very closely, which is 84.05% institutions for Iovance Biotherapeutics Inc that are currently holding shares of the company. VANGUARD GROUP INC is the top institutional holder at IOVA for having 25.95 million shares of worth $208.12 million. And as of 2024-06-30, it was holding 9.7478 of the company’s outstanding shares.
The second largest institutional holder is PERCEPTIVE ADVISORS LLC, which was holding about 25.93 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.1052 of outstanding shares, having a total worth of $207.98 million.
